Carlo Bartolozzi

Carlo Bartolozzi

Auto-generated profile, based on publicly available information

Carlo Bartolozzi

Department of Diagnostic and Interventional Radiology, University of Pisa, Pisa, Italy

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2007 in European Radiology
Verified
Journal Article
Closed access
PDF file
CBCarlo Bartolozzi
Carlo Bartolozzi
laura crocettilaura crocetti
laura crocetti
RLRiccardo Lencioni
Riccardo Lencioni
DCDania Cioni
Dania Cioni
CPClotilde Della Pina
Clotilde Della Pina
DCDaniela Campani
Daniela Campani

1 April 2010 in Radiology
Verified
Journal Article
Closed access
IBIrene Bargellini
Irene Bargellini
CVClaudio Vignali
Claudio Vignali
RCRoberto Cioni
Roberto Cioni
PPPasquale Petruzzi
Pasquale Petruzzi
ACAntonio Cicorelli
Antonio Cicorelli
CBCarlo Bartolozzi
Carlo Bartolozzi
PURPOSE: To retrospectively evaluate the clinical outcome of patients with hepatocellular carcinoma (HCC) who exceeded the Milan criteria, who underwent transarterial chemoembolization (TACE) before orthotopic liver transplantation (OLT), to determine the value of computed tomography (CT)-based tumor response to TACE as a preoperative selection criterion for OLT.\ud \ud \ud \ud MATERIALS AND METHODS: The study included 33 patients with HCC who exceeded the Milan criteria and underwent OLT after TACE. Informed written consent was obtained before TACE and OLT. Institutional review board approval was not required. Tumor response to TACE was evaluated at 1 month with CT according to amended Response Evaluation Criteria in Solid Tumours (RECIST) guidelines. In the explanted liver, degree of tumor necrosis (> or = 90%, 50%-89%, or < 50%), residual tumor stage and grade, and presence of microvascular invasion were assessed. Follow-up after OLT ranged from 1 to 143 months.\ud \ud \ud \ud RESULTS: After TACE, CT showed complete tumor response (CR) in 18 (55%) patients. On the explanted liver, tumor necrosis was rated 90% or greater in 20 (61%) patients, with a good correlation with CT. Microvascular invasion was observed in nine (27%) of 33 patients; none of them were reported to have a CR at CT. The 5-year cumulative survival rate after OLT was 72.5%; it was significantly (P = .003) higher in patients with a CR (94.4%) compared with patients with a partial response (PR) (45.4%) and stable disease (50%). The 5-year cumulative recurrence-free rate after OLT was 74.4%; it was not affected by the tumor nodule size and number, whereas it was significantly (P = .008) higher in patients with a CR (94.4%) compared with patients with a PR (46.7%) and stable disease (50%).\ud \ud \ud \ud CONCLUSION: In patients with HCC who exceeded the Milan criteria, a CR after TACE, on the basis of amended RECIST guidelines, is associated with excellent posttransplantation outcomes. Therefore, 1-month response to TACE assessed at CT may represent a valid selection criterion for OLT

28 January 2011 in Skeletal Radiology
Verified
Journal Article
Closed access
PDF file
VZVirna Zampa
Virna Zampa
IBIrene Bargellini
Irene Bargellini
LRLoredana Rizzo
Loredana Rizzo
FTFrancesca Turini
Francesca Turini
SOSimona Ortori
Simona Ortori
CBCarlo Bartolozzi
Carlo Bartolozzi

17 January 2011 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
Rodolfo SaccoRodolfo Sacco
Rodolfo Sacco
IBIrene Bargellini
Irene Bargellini
Gianluigi  GiannelliGianluigi Giannelli
Gianluigi Giannelli
MBMarco Bertini
Marco Bertini
EBElena Bozzi
Elena Bozzi
CBCarlo Bartolozzi
Carlo Bartolozzi
Hepatocellular carcinoma (HCC) is the fifth most common neoplasia in the world. In the past, treatment of advanced HCC with conventional antineoplastic drugs did not result in satisfactory outcomes: recently, in this patient population the oral multikinase inhibitor sorafenib has been able to induce a statistically significant improvement of overall survival. Similarly to other anti-angiogenic drugs employed in other tumour types, also sorafenib seldom induces the dimensional tumour shrinking usually observed with conventional cytotoxic drugs: data gathered from studies carried out with sorafenib and other competitors under development do not report any complete response in HCV-induced HCC.

1 June 2009 in Digestive Diseases
Verified
Journal Article
Closed access
CBCarlo Bartolozzi
Carlo Bartolozzi
VBValentina Battaglia
Valentina Battaglia
EBElena Bozzi
Elena Bozzi
Thanks to the sensible and continuous improvements achieved, magnetic resonance imaging (MRI) can nowadays be considered the most accurate modality to image the liver. Moreover, the technique is the only one able to provide at the same time information about intracellular and vascular changes occurring in parenchymas. For these reasons, MRI plays a major role in the surveillance and follow-up of patients with cirrhosis. If a baseline MR study investigates the progressive alteration of lesion architecture, grading, stromal component, as well as intracellular content of fat, glycogen, or metal ions, thus leading to a frequent confident diagnosis of lesion nature, a dynamic study provides additional information about lesion vascular enhancement, which may represent the only clue for the differential diagnosis between premalignant and malignant lesions. In addition, the introduction of hepatobiliary contrast agents has further implemented the diagnostic confidence of the technique, permitting to explore the so-called grey area in which significant histological changes are already present without an evident arterial supply of the nodule. Although in the evaluation of liver pathologies MRI is mainly applied in the study of cirrhosis, the technique also plays a fundamental role in the assessment of other primitive liver malignancies, such as fibrolamellar carcinoma or cholangiocarcinoma. In these cases in particular, MRI is required to pose a differential diagnosis with other liver malignancies (such as metastases), and, once the nature of the neoplasm is assessed, to give an accurate locoregional staging.

1 July 2012 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
Rodolfo SaccoRodolfo Sacco
Rodolfo Sacco
IBIrene Bargellini
Irene Bargellini
BGBarbara Ginanni
Barbara Ginanni
MBMarco Bertini
Marco Bertini
Lorenzo FaggioniLorenzo Faggioni
Lorenzo Faggioni
CBCarlo Bartolozzi
Carlo Bartolozzi
Background and aims: Prospective randomized trials have proven that sorafenib is a valid treatment option for patients with advanced-stage hepatocellular carcinoma (HCC). The aim of the present study is to evaluate the effectiveness and safety of sorafenib in patients encountered in routine clinical practice. Methods: From September 2008 to March 2011, 42 cirrhotic patients (30 male; 12 female; mean age: 70.2 ± 7.6 years; range: 56-85 years) with HCC of Barcelona Clinic Liver Cancer stage B (n = 5) or C (n = 37; mean size: 66.6 ± 42.3 mm; mean number per patient: 3.3 ± 2.8) were treated with sorafenib at either a standard dose of 800 mg/day (n = 29; 69.1%) or at 400 mg/day with subsequent dose escalation (ramp-up strategy; n = 13, 30.9%). Baseline clinical parameters were comparable. Clinical data and side effects, laboratory analyses (in particular, serum α-fetoprotein) and radiological data (tumor response according to amended RECIST criteria) were assessed every 3 months. Survival was calculated by Kaplan-Meier analysis. Results: Mean follow-up was 12.2 ± 9 months (range: 1-32 months). Median overall survival was 26.1 months with overall 6- and 12-month survival rates of 92.1 and 85%, respectively. Median time to radiological progression was 8 months. The progression-free rate was 64.3%. Fatigue, skin disorders and diarrhea were the most frequent grade 3-4 side effects. Treatment discontinuation occurred in 25 patients. The starting dose for the last 13 enrolled patients was 400 mg/day; in the absence of toxicity this dosage was gradually increased to 800 mg/day after 3 weeks ('ramp-up strategy). No grade 3/4 adverse events were observed in the ramp-up group. Conclusion: Sorafenib is a valid treatment option for advanced-stage HCC. Starting at a lower dosage may allow prolonged compliance to treatment and might be considered according to patient tolerance